Primary central nervous system lymphoma in a patient treated with natalizumab

Andreas Schweikert, Marcus Kremer, Florian Ringel, Thomas Liebig, Justus Duyster, Olaf Stüve, Bernhard Hemmer, Achim Berthele

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy. PCNSL is a disease of the elderly, with the majority of patients being diagnosed in the 7th to 8th decade of life. Immunodeficiency, iatrogenic immunosuppression, and some autoimmune diseases are known as predisposing conditions, and in these patients PCNSL peaks in the 4th decade. Because there is no increased prevalence of PCNSL in MS, and the patient was otherwise not immunocompromised, an association between natalizumab therapy and PCNSL cannot be ruled out.

Original languageEnglish (US)
Pages (from-to)403-406
Number of pages4
JournalAnnals of Neurology
Volume66
Issue number3
DOIs
StatePublished - 2009

Fingerprint

Lymphoma
Central Nervous System
Relapsing-Remitting Multiple Sclerosis
Immunosuppression
Autoimmune Diseases
Multiple Sclerosis
Natalizumab
Therapeutics

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Schweikert, A., Kremer, M., Ringel, F., Liebig, T., Duyster, J., Stüve, O., ... Berthele, A. (2009). Primary central nervous system lymphoma in a patient treated with natalizumab. Annals of Neurology, 66(3), 403-406. https://doi.org/10.1002/ana.21782

Primary central nervous system lymphoma in a patient treated with natalizumab. / Schweikert, Andreas; Kremer, Marcus; Ringel, Florian; Liebig, Thomas; Duyster, Justus; Stüve, Olaf; Hemmer, Bernhard; Berthele, Achim.

In: Annals of Neurology, Vol. 66, No. 3, 2009, p. 403-406.

Research output: Contribution to journalArticle

Schweikert, A, Kremer, M, Ringel, F, Liebig, T, Duyster, J, Stüve, O, Hemmer, B & Berthele, A 2009, 'Primary central nervous system lymphoma in a patient treated with natalizumab', Annals of Neurology, vol. 66, no. 3, pp. 403-406. https://doi.org/10.1002/ana.21782
Schweikert, Andreas ; Kremer, Marcus ; Ringel, Florian ; Liebig, Thomas ; Duyster, Justus ; Stüve, Olaf ; Hemmer, Bernhard ; Berthele, Achim. / Primary central nervous system lymphoma in a patient treated with natalizumab. In: Annals of Neurology. 2009 ; Vol. 66, No. 3. pp. 403-406.
@article{f3a4263fd3af4ee792b803a451816041,
title = "Primary central nervous system lymphoma in a patient treated with natalizumab",
abstract = "A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy. PCNSL is a disease of the elderly, with the majority of patients being diagnosed in the 7th to 8th decade of life. Immunodeficiency, iatrogenic immunosuppression, and some autoimmune diseases are known as predisposing conditions, and in these patients PCNSL peaks in the 4th decade. Because there is no increased prevalence of PCNSL in MS, and the patient was otherwise not immunocompromised, an association between natalizumab therapy and PCNSL cannot be ruled out.",
author = "Andreas Schweikert and Marcus Kremer and Florian Ringel and Thomas Liebig and Justus Duyster and Olaf St{\"u}ve and Bernhard Hemmer and Achim Berthele",
year = "2009",
doi = "10.1002/ana.21782",
language = "English (US)",
volume = "66",
pages = "403--406",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Primary central nervous system lymphoma in a patient treated with natalizumab

AU - Schweikert, Andreas

AU - Kremer, Marcus

AU - Ringel, Florian

AU - Liebig, Thomas

AU - Duyster, Justus

AU - Stüve, Olaf

AU - Hemmer, Bernhard

AU - Berthele, Achim

PY - 2009

Y1 - 2009

N2 - A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy. PCNSL is a disease of the elderly, with the majority of patients being diagnosed in the 7th to 8th decade of life. Immunodeficiency, iatrogenic immunosuppression, and some autoimmune diseases are known as predisposing conditions, and in these patients PCNSL peaks in the 4th decade. Because there is no increased prevalence of PCNSL in MS, and the patient was otherwise not immunocompromised, an association between natalizumab therapy and PCNSL cannot be ruled out.

AB - A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy. PCNSL is a disease of the elderly, with the majority of patients being diagnosed in the 7th to 8th decade of life. Immunodeficiency, iatrogenic immunosuppression, and some autoimmune diseases are known as predisposing conditions, and in these patients PCNSL peaks in the 4th decade. Because there is no increased prevalence of PCNSL in MS, and the patient was otherwise not immunocompromised, an association between natalizumab therapy and PCNSL cannot be ruled out.

UR - http://www.scopus.com/inward/record.url?scp=70349440918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349440918&partnerID=8YFLogxK

U2 - 10.1002/ana.21782

DO - 10.1002/ana.21782

M3 - Article

VL - 66

SP - 403

EP - 406

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 3

ER -